AbbVie Q2 Revenue Tops $17.0B on Immunology Strength, but Trims Profit Outlook on Apogee Deal

AbbVie reported second-quarter 2026 revenue of $17.0 billion, up 10.2% year-over-year and above market expectations, according to an SEC Form 8-K filing. Shares of AbbVie fell 2.22% to $257.45 on the day.

📊 Price at Time of Writing (July 31, 2026, 23:11 KST)
$257.45 ▼ -2.22%

Q2 Results at a Glance

AbbVie's second-quarter revenue was driven by its immunology business. Sales of Skyrizi and Rinvoq surged, while sales of the older drug Humira declined sharply. Adjusted operating margin (excluding interest, taxes, and depreciation/amortization) came in at 48.3%.

• Revenue: $17.0 billion, +10.2% year-over-year
• Earnings per share (EPS): $2.03 GAAP (+290.4% YoY), $3.65 adjusted (+22.9% YoY)
• Operating margin (as a % of revenue): 37.9% GAAP, 48.3% adjusted (excluding interest, taxes, and depreciation/amortization)

Guidance Update

AbbVie lowered its full-year 2026 adjusted EPS guidance to a range of $13.87 to $14.07, down from $13.91 to $14.11 previously. The revision reflects a $0.14-per-share dilutive impact from the pending acquisition of Apogee Therapeutics, expected to close in the third quarter. It also includes a $0.58-per-share charge tied to acquisition-related research and development expenses (IPR&D and milestone payments). AbbVie Chairman and CEO Robert Michael said the Apogee deal will strengthen the company's immunology franchise and enhance shareholder value, adding that AbbVie's long-term outlook remains very strong.

Market Reaction

Reuters and other outlets noted that AbbVie's second-quarter revenue beat market expectations. Barron's and Yahoo Finance, however, reported that the lowered profit outlook tied to the Apogee acquisition and other earnings metrics fell short of market expectations. Following the results, AbbVie shares fell 2.22% to $257.45. The specific purchase price for the Apogee Therapeutics acquisition was not disclosed in the filing.

Segment Breakdown

• Immunology: $8.786 billion, +15.1% year-over-year
• Neuroscience: $3.228 billion, +20.3% year-over-year
• Oncology: $1.650 billion, -1.5% year-over-year
• Aesthetics: $1.282 billion, +0.3% year-over-year

This article was automatically generated based on the original SEC Form 8-K filing and media reports, with the aim of delivering key data promptly after the announcement. Readers are encouraged to review the company's official filing before making trading decisions. Prices reflect the time of writing and may differ from current levels.